Publisher： John Wiley & Sons Inc
E-ISSN： 1365-2249|181|1|100-109
ISSN： 0009-9104
Source： CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol.181, Iss.1, 2015-07, pp. : 100-109
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
SummaryHuman leucocyte antigen (HLA)‐G has a tolerogenic function and could play a role in the pathogenesis of immune‐mediated diseases, including systemic sclerosis (SSc). The aim of this study was to evaluate HLA‐G serum expression (sHLA‐G) and the HLA‐G gene 14 base pairs (bp) insertion/deletion (del−/del+) polymorphism in patients with Ssc, to search for possible associations with clinical and laboratory variables. sHLA‐G was measured by enzyme‐linked immunosorbent assay (ELISA) in sera from 77 patients with SSc and 32 healthy donors (HD); the 14 bp del−/del+ polymorphism was evaluated by polymerase chain reaction (PCR) amplification of peripheral blood mononuclear cells (PBMC) genomic DNA. Receiver operating characteristics (ROC) analysis identified the HLA‐G cut‐off that best discriminated dichotomized clinical and serological variables, that was subsequently employed to subdivide SSc patients into HLA‐G high (HLA‐G+) and low (HLA‐G−) profile groups. sHLA‐G were not statistically different between SSc patients and HD, nor between distinct SSc autoantibody subsets. Subdividing SSc patients by HLA‐G positivity or negativity yielded significant differences for the modified Rodnan skin score (mRss) (P = 0·032), ‘general’ (P = 0·031) and ‘kidney’ (P = 0·028) Medsger severity scores (MSS) and disease activity index, and especially Δ heart/lung (P = 0·005). A worse ‘general’ MSS (P = 0·002) and Δ heart/lung (P = 0·011) were more frequent in the low sHLA‐G group. These two variables and mRss were associated with sHLA‐G levels at logistic regression analysis. Treatment had no influence on sHLA‐G. Moreover, a higher frequency of scleredema was detected in the del+/del+ than the del‐/del+ group (P = 0.04). These data suggest modulatory effects of sHLA‐G on SSc. Prospective studies are needed to investigate a role in predicting the disease course.
Related content
Access to resources
Recommend
CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 179, Iss. 2, 2015-02 ,pp. :
Clinical implication of human leukocyte antigen (HLA)‐F expression in breast cancer
PATHOLOGY INTERNATIONAL, Vol. 65, Iss. 11, 2015-11 ,pp. :